comprehensive -WSS

comprehensive

author：focus 2025-09-11 18:47:07 - browse：969

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Readout Newsletter: Parkinson's study, Gilead, CG Oncology

focus

hotspot

WSS

The inclusion problem at the heart of rehabilitation research

Dobbs anniversary: the lost opportunity of abortion as health care

Printout prescription drug information shouldn’t go digital

Walensky prepares to leave CDC — and Congress — behind

Medicare bonuses could stop drug shortages under Senate plan

Anesthesiologist group: stop taking Ozempic before surgery

hotspot

comprehensive

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Printout prescription drug information shouldn’t go digital

Cancer drug shortages should be causing more outrage

Jerome Adams on the need for new antivirals for Covid

What does generative AI mean for health care? We asked experts

Dobbs anniversary: the lost opportunity of abortion as health care

Medical leaders decry Supreme Court decision on affirmative action

Jerome Adams on the need for new antivirals for Covid

Activists slam private health insurers over coverage restrictions

Cancer drug shortages should be causing more outrage

focus

Duchenne breakthrough therapy leaves behind pioneering families

As demand for Covid shots wanes, Moderna seeks its next success

Flu vaccine reformulation won't be easy, manufacturers warn

Future doctors need a strong humanities education

Maisha Meds is a PBM, but don't call it that

As demand for Covid shots wanes, Moderna seeks its next success

focus

hotspot

hotspot

focus